Innovations in the prevention and treatment of postpartum hemorrhage: Analysis of a novel medicines development pipeline database.

BACKGROUND

A significant barrier to improving prevention and treatment of postpartum hemorrhage (PPH) is a lack of innovative medicines that meet the needs of women and providers, particularly those in low-and middle-income countries (LMICs). The Accelerating Innovation for Mothers (AIM) project established a new database of candidate medicines under development for five pregnancy-related conditions between 2000 and 2021.

OBJECTIVE

To systematically identify and rank candidates for prevention and treatment of PPH.

SEARCH STRATEGY

Adis Insight, Pharmaprojects, WHO ICTRP, PubMed, and grant databases were searched to develop the AIM database.

SELECTION CRITERIA

AIM database was searched for candidates being evaluated for PPH prevention and treatment, regardless of phase.

DATA COLLECTION AND ANALYSIS

Candidates were ranked as high, medium, or low potential based on prespecified criteria. Analysis was primarily descriptive, describing candidates and development potential.

MAIN RESULTS

Of the 444 unique candidates, only 39 pertained to PPH. One was high potential (heat-stable/inhaled oxytocin) and three were medium potential (melatonin, vasopressin and dofetilide via nanoparticle delivery).

CONCLUSION

The pipeline for new PPH medicines is concerningly limited, lacking diversity, and showing little evidence of novel technologies. Without significant investment in early-phase research, it is unlikely that new products will emerge.